Enfusion shares are trading lower after JP Morgan downgraded the stock from Neutral to Underweight and lowered its price target from $11 to $9.
Portfolio Pulse from Benzinga Newsdesk
Enfusion's stock (ENFN) is trading lower following a downgrade by JP Morgan from Neutral to Underweight, accompanied by a reduction in the price target from $11 to $9.
January 30, 2024 | 4:45 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Enfusion's stock price is likely to experience downward pressure in the short term due to JP Morgan's downgrade and lowered price target.
Analyst downgrades typically lead to a negative perception among investors, potentially causing a sell-off. The reduction in price target further suggests a bearish outlook on the stock's value, which can influence investor sentiment and stock price negatively in the short term.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100